Naltrexone augmentation of neuroleptics in schizophrenia.

This study was conducted to determine whether the addition of naltrexone to ongoing neuroleptic treatment would facilitate the reduction in positive or negative symptoms in patients with schizophrenia. Twenty-one patients meeting DSM-III criteria for schizophrenia were enrolled; all patients had been stabilized for at least 2 weeks on their dosage of neuroleptic medicine before entering the study. Patients were randomized to receive either placebo or naltrexone 200 mg/day for 3 weeks in addition to their neuroleptic. Patients randomized initially into the placebo arm were crossed over to receive naltrexone in a single-blind fashion for 3 additional weeks. All patients were rated weekly with the Brief Psychiatric Rating Scale (BPRS). Fifteen patients received placebo and six received naltrexone in the first 3 weeks. No significant effects of naltrexone on total BPRS scores or BPRS subscale scores were observed. Patients who received naltrexone on a single-blind basis at the end of the placebo-controlled trial demonstrated a transient exacerbation in negative symptoms as reflected by the total BPRS score and the BPRS Withdrawal-Retardation subscale score. Repeated-measures analysis of variance (ANOVA) on the BPRS total score of the subsequent treatment with naltrexone showed a trend for a significance in the drug by time effect. Repeated-measures ANOVA on the BPRS Withdrawal-Retardation subscale of the subsequent treatment with naltrexone showed a significant drug by time effect. The current data failed to indicate a clinical benefit when naltrexone was added to the neuroleptic regimen. Other potential applications of naltrexone in schizophrenia are addressed.

[1]  J. Kelsoe,et al.  Beneficial Effects of Nalmefene Augmentation in Neuroleptic-Stabilized Schizophrenic Patients , 1993, Neuropsychopharmacology.

[2]  A. Alterman,et al.  Naltrexone in the treatment of alcohol dependence. , 1992, Archives of general psychiatry.

[3]  B. Rounsaville,et al.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study. , 1992, Archives of general psychiatry.

[4]  T. H. Lee,et al.  Baclofen intoxication: report of four cases and review of the literature. , 1992, Clinical neuropharmacology.

[5]  R. Drake,et al.  Alcohol Use and Abuse in Schizophrenia: A Prospective Community Study , 1989, The Journal of nervous and mental disease.

[6]  W. Verhoeven,et al.  Repeated naloxone administration in schizophrenia: A phase II world health organization study , 1989, Biological Psychiatry.

[7]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[8]  J. Csernansky,et al.  Rating scales in research: The case of negative symptoms , 1987, Psychiatry Research.

[9]  D. Naber,et al.  Naloxone treatment for five days ineffective in schizophrenia , 1983, Acta psychiatrica Scandinavica.

[10]  F. Goodwin,et al.  Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients. , 1981, The American journal of psychiatry.

[11]  D. Segal,et al.  Behavioral effects of methadone in schizophrenic patients. , 1981, The American journal of psychiatry.

[12]  Gallant Dm,et al.  An oral opiate antagonist in chronic schizophrenia: a pilot study. , 1977 .

[13]  L. Terenius,et al.  Increased CSF levels of endorphines in chronic psychosis , 1976, Neuroscience Letters.

[14]  G. B. Dowling,et al.  Vitamin D in cutaneous tuberculosis. , 1947, Lancet.

[15]  J. Kleinman,et al.  Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients. , 1991, Life sciences.

[16]  K. Mueser,et al.  Narcotic Antagonists in Schizophrenia: A Methodological Review , 1983 .

[17]  John M. Davis Dose equivalence of the anti-psychotic drugs , 1974 .